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Background: Obstructive sleep apnea-hypopnea syndrome (OSAHS) is associated with cardiovascular
morbidity and mortality, which can be improved by using continuous positive airway pressure (CPAP)
therapy. However, the pathophysiological links between the two kinds of disease and the mechanism of the
CPAP effect remain incompletely understood. We aimed to inquire into the myocardial involvement in this
relationship. We suggested that serum brain natriuretic peptide (BNP) is sensitive enough to detect
myocardial stress caused by OSAHS.
Design and methods: Sixty-four subjects without cardiovascular disease (21 controls, 24 normotensive OSAHS
patients, and 19 hypertensive OSAHS patients) were analyzed for serum BNP at baseline and serially over
6 months. CPAP was applied to 23 patients with severe OSAHS.
Results: At baseline, the serum BNP levels were significantly higher (p0.0001) in the OSAHS group
(22.3914.79 pg/ml) than in the control group (9.296.75 pg/ml). Increased serum BNP levels were significantly
associated with mean transcutaneous oxygen saturation (SpO2) (pB0.0001), minimal SpO2 (p0.002), oxygen
desaturation index (p0.001), and total sleep time spent with SpO2 lower than 90% (p0.002). All patients
with elevated BNP levels (]37 pg/ml) had moderate or severe OSAHS (11/43 OSAHS patients). The more
severe the OSAHS, the higher the BNP levels were. However, only the difference between severe and mild
OSAHS was statistically significant (p0.029). Hypertensive OSAHS patients had the highest baseline BNP
levels (27.7916.74 pg/ml). They were significantly higher (p0.001) than in normotensive OSAHS patients
(18911.72 pg/ml) (p0.039) and the controls (9.296.75 pg/ml). As compared with baseline, treatment
with CPAP significantly decreased BNP levels in both hypertensive and normotensive OSAHS patients
(respectively, from 36916.10 to 29.7914.29 pg/ml, pB0.001, and from 20910.09 to 1698.98 pg/ml,
pB0.001). In contrast, the BNP levels slightly increased in the controls (from 9.296.75 to 9.597.02 pg/ml,
p0.029), but there was no statistically significant difference in comparison with the baseline value. The effect
of CPAP on BNP levels was more marked in patients with higher baseline BNP levels and those with the most
prolonged nocturnal desaturation (p0.001, r0.65). It was also more marked in hypertensive OSHAS
patients (p0.015, r0.72) in comparison with normotensive OSAHS patients (p0.03, r0.62).
Conclusion: BNP seems to be sensitive enough to detect myocardial stress caused by OSAHS. As such, it
is a potential marker for screening of preclinical cardiovascular damage in patients with untreated
OSAHS. Application of CPAP decreases levels significantly in normotensive and particularly in hypertensive
OSAHS. These findings are consistent with previous results suggesting the potential benefits of CPAP on
cardiovascular outcome in OSAHS patients.
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bstructive sleep apnea-hypopnea syndrome
(OSAHS) is a common sleep-related breathing
disorder that occurs in about 47% of the general
adult population (1). It is characterized by recurrent
episodes of complete or partial upper airway obstruction
during sleep, resulting in oxygen desaturation, sleep
fragmentation, and daytime sleepiness (2).
Recent studies have shown a large body of epidemiologic
evidence linking the OSAHS with important cardiovascu-
lar morbidity and mortality (3). However, the underlying
pathophysiologic mechanisms are not fully understood,
nor is the potential role of cardiac biomarkers in these
states. Recently, there has been growing interest in the
potential relationship between OSAHS and brain natri-
uretic peptide (BNP) regulation (4).
BNP is a cardiac neuro-hormone secreted predomi-
nantly by the left ventricular myocytes in response tovolume
expansion and pressure overload (5). Because OSAHS has
been suggested as a probable cause of increased ventricular
load and therefore ventricular distension during periods of
apnea, it has been proposed that BNP levels could be useful
as a diagnostic and prognostic marker in patients with
OSAHS (6). Previous studies on the association between
biomarkers and the presence and severity of OSAHS have
revealed conflicting results (7). While some studies re-
ported increasing levels of BNP in patients with OSAHS
(8) and reduced BNP levels with continuous positive
airway pressure (CPAP) treatment (9), others have not
found any association (10). In addition, most studies are
small and based on symptomatic patients referred to sleep
clinics. Therefore, the association between OSAHS and
BNP levels in the general population remains largely
unknown (8).
The aim of this study was to analyze the possible
association between OSAHS during the night and levels
of BNP the following morning in a community-based
sample of patients. We also evaluated the effect of CPAP
therapy on BNP levels.
Methods
Subjects and protocol
This was a prospective, controlled, cross-sectional study
performed between September 2013 and September 2014
at the Hedi Chaker University Hospital of Sfax, Tunisia.
The study was approved by the local ethics committee,
and informed consent was obtained from each patient
enrolled in the study. We included subjects older than
18 years with suspected OSAHS. Exclusion criteria
included refusal to participate in the study, previously
diagnosed sleep-disordered breathing, chronic obstructive
pulmonary diseases or other severe lung disorders, a history
of cerebrovascular or cardiovascular events, uncontrolled
hypertension, psychiatric disorders, diabetes mellitus, hyper-
lipidemia, hypercholesterolemia, malignancy, inflammatory
diseases, dysthyroidism, a history of recent facial trauma/
operation, pregnancy, and the use of sedatives or muscle
relaxants.
During the study, 456 patients were screened for
OSAHS. Only 64 subjects met the inclusion/exclusion
criteria and were enrolled in this study: 21 healthy normo-
tensive subjects as controls, 24 normotensive OSAHS
patients, and 19 hypertensive OSAHS patients.
Clinical assessment
Patient history was obtained with the help of a structured
interview. We collected demographic variables (age, sex),
current cigarette smoking status, history of preexisting
diseases, and current drug use. Daytime sleepiness was esti-
mated using the Arabic version of the Epworth sleepiness
scale (ESS) (10). In addition to standard physical exam-
ination, neck circumference, body weight, and height were
measured. Body mass index (BMI) was calculated as
kg/m2. Daytime blood pressure was measured in the right
upper arm using an automatic oscillometric device after a
rest of at least 10 min in a seated position. The main awake
blood pressure was calculated based on three measure-
ments on the day of admission. Patients were considered
normotensive if they had no history of hypertension,
their systolic blood pressure was 5139 mmHg, and their
diastolic blood pressure was 589 mmHg. Patients with
a history of hypertension or systolic blood pressure
]140 mmHg and diastolic ]90 mmHg were classified as
hypertensive (11).
Nocturnal polygraph recording
All patients underwent overnight type III polysomno-
graphy (PSG) (EmblaTM N7000, ResMed Corp., San
Diego, CA, United States) according to standard techni-
ques. Flow was monitored by an oronasal air pressure
transducer (EmblaTM N7000, ResMed Corp., San Diego,
CA, United States), thoracic and abdominal respiratory
effort by uncalibrated impedance plethysmography belts
(EmblaTM N7000, ResMed Corp., San Diego, CA,
United States), pulse oximetry, and body position.
Snoring was recorded by a microphone (EmblaTM N7000,
ResMed Corp., San Diego, CA, United States) placed on
the anterior neck. A priority in the study was to make
recommendations about avoiding caffeinated drinks and
food, alcohol, and drugs that could interfere with sleep
architecture. Respiratory parameters were scored by
one doctor according to the standard criteria of the
American Academy of Sleep Medicine (AASM). Based
on the guidelines of the AASM published in 2012,
obstructive apnea was defined as a ]90% decrease in
airflow relative to the basal amplitude persisting for at least
10 sec in the presence of thoracic and abdominal move-
ments. Hypopnea was defined as a ]50% decrease in the
airflow amplitude relative to the baseline with an asso-
ciated ]3% oxygen desaturation or arousal persisting for
at least 10 sec (12). It was scored as an obstructive event
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when the inspiratory flow signal showed a flow limitation
or snoring occurred. The numbers of apneic and hypopneic
episodes per hour of estimated sleep time were reported as
the apnea-hypopnea index (AHI). The presence of OSAHS
was defined as an AHI ]5 events per hour (2). OSAHS
was graded according to AHI as mild (5/h 5AHIB15/h),
moderate (15/h5AHIB30/h), or severe (AHI ]30/h).
Patients without any evocative symptoms apart from
snoring were classified as controls if polygraphic screening
showed an AHI B5/h.
CPAP therapy
Nocturnal CPAP ventilation was offered to all patients
with severe OSAHS using the S9 Elite (ResMed Ltd Bella
Vita, NSW, Australia). CPAP titration was conducted
with auto-titrating devices during a short hospitalization.
Detailed explanation of CPAP use was provided, and
control visits were conducted 1, 3, and 6 months after
CPAP initiation. Compliance was assessed by the CPAP
card data at each appointment. Benefits and side effects
associated with CPAP therapy were also assessed. Device
usage for 4 h per day and for 5 days a week was
accepted as the only criterion of good compliance (13).
Blood collection and analysis
Blood samples for BNP were taken using standard
venipuncture between 7:00 and 9:00 a.m. after a 12-h
fast and separated immediately after centrifugation at 48C,
1,800g for 20 min. Blood samples were obtained again
after 6 months from those with CPAP therapy and those
who received no treatment. The plasma levels of BNP
were measured using a chemiluminescence immunoassay
on the ADVIA Centaur Analyzer Siemens Healthcare
Diagnostics (Saint-Denis, France). A value of BNP ]37
pg/ml was regarded as elevated, in accordance with the
reference value of the method.
Other examinations
Electrocardiogram, chest X-ray, and pulmonary function
tests were performed for all OSAHS patients as well as
for controls. Lung function parameters included forced
vital capacity (FVC) and forced expiratory volume in
1 sec (FEV1). Each parameter was expressed as a
percentage of the predicted value.
Statistics
Statistical analysis was performed using SPSS 17 (SPSS,
Inc., Chicago, IL, USA) for Windows. Data are
presented as frequencies, percentages, mean9standard
deviation, or median. Differences between consecutive
BNP values were assessed by a one-way analysis of
variance test with a Bonferroni correction. A value of
pB0.05 was considered significant.
Results
Clinical and sleep characteristics of the study
population
Sixty-four subjects (mean age44.4910.90 years, 32
males/32 females, BMI33.896.30 kg/m2) were included
in the study: 21 in the control group (Group 1) and 43 in
the OSAHS group (Group 2; AHI28916.95). OSAHS
was severe in 17 patients (39.5%), moderate in 16 (37.2%),
and mild in 10 (23.3%). Of the 43 patients with OSAHS, 24
were normotensive (Group 3), while 19 were hypertensive
(Group 4).
The OSAHS and control groups were similar in age, sex
distribution, BMI, smoking status, and blood pressure.
In addition, patient demographics (age, sex, and smoking
status) were similar in the three study groups. However,
BMI was significantly higher in hypertensive OSAHS
patients in comparison with normotensive OSAHS pa-
tients (p0.032) but not compared with the controls.
Based on the ESS, patients with OSAHS were signifi-
cantly more somnolent than control subjects (p0.013).
Similarly, the mean ESS was significantly higher in
hypertensive OSAHS patients than normotensive OSAHS
patients (p0.015). The highest AHI was observed in
hypertensive OSAHS patients. The oxygen desaturation
index (ODI) was significantly higher in OSAHS patients
in comparison with controls (p0.0001), but it was not
significantly different between hypertensive and normo-
tensive OSAHS. Spirometric measurements (FEV1, FVC,
and FEV1/FVC) did not differ among the four groups.
The baseline characteristics of the final study population
are shown in the Table 1.
Levels of BNP and clinical data
Subjects were also divided into two groups based on
whether the BNP level was above or below the cut-off
value. At first presentation, the plasma levels of BNP in
all subjects ranged from 1.9 to 57 pg/ml, with a median of
17.9914.17 pg/ml.
Levels of BNP and polygraph data
Patients with increased levels of BNP were significantly
older than those with normal levels (p0.03). In contrast,
low or high levels of BNP were not associated with
sex ratio, BMI, smoking status, ESS, blood sugar blood
levels, or creatinine clearance. Increased levels of BNP
were significantly more frequent among patients with
OSAHS (25.6%) in comparison with the control group
(0%) (p0.011). Similarly, the serum BNP levels were
significantly higher in the OSAHS group (22.3914.79
pg/ml) than in the controls (9.296.75 pg/ml) (p0.0001).
In addition, increased serum BNP levels were significantly
associated with mean transcutaneous oxygen saturation
(SpO2) (pB0.0001), minimal SpO2 (p0.002), ODI (p
0.001), and total sleep time with SpO2B90% (TST90)
(p0.002) (Table 2).
Serum BNP level change under nasal CPAP
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BNP levels by OSAHS classification are shown in
Table 3. All patients with high BNP levels had moderate
or severe OSAHS (11/43 OSAHS patients) (Fig. 1). There
was also a dose  response relationship between increas-
ing severity of sleep apnea and elevated BNP. However,
only the difference between severe and mild OSAHS was
statistically significant (p0.029).
Baseline characteristics of the AHI groups are shown in
Table 4. There were no significant differences between the
two groups in age, sex ratio, smoking status, BMI, average
blood pressure, ESS, spirometric indices, or creatinine
clearance. In participants with high AHI (]5/h),
mean SpO2 and minimal SpO2 were significantly lower
(pB0.001), while blood sugar levels were significantly
higher (p0.029), as well as mean BNP level (22.3914.79
pg/ml vs. 9.296.75 pg/ml among participants with an
AHIB5, pB0.0001). This association between high
baseline AHI and higher baseline BNP levels remained
after adjustment for confounders of blood sugar levels.
Hypertensive OSAHS patients had the highest baseline
BNP level (27.7916.74 pg/ml). It was significantly higher
than in normotensive OSAHS patients (18911.72 pg/ml)
(p0.039) and in controls (9.296.75 pg/ml) (p0.001).
Normotensive OSAHS patients had higher baseline BNP
levels than controls, but there was no statistically signifi-
cant difference between the two groups (p0.058) (Fig. 2).
Effect of CPAP therapy
Twenty-seven patients who were treated with CPAP were
reexamined after a follow-up of 6 months. The integrated
hour meter showed that only 23 patients used CPAP
regularly. Four patients had poor CPAP compliance and
were excluded from the CPAP trial.
Table 1. Clinical characteristics, results of sleep studies, and spirometric measurements: comparison of OSAHS patients,
normotensive and hypertensive patients, and controls









Age (years) 41.3910.07 46911.05 43.8912.50 48.698.40 44.4910.90
Sex (male/female) 10/11 22/21 14/10 8/11 32/32
Smoking status (%) 19.0 27.9 33.3 21.1 25.0
ESS (mean9SD) 7.794.79 10.393.24* 9.693.40 10.292.87** 9.493.97
BMI (kg/m2) 32.995.90 34.296.51 3297.20 36.994.30*** 33.896.30
Average BP (mmHg) 9.490.60 9.690.70 9.290.50 10.090.70**** 9.590.70
AHI (mean9SD) 2.691.27 28.0916.95 28.2918 29.7916 19.65918.34
ODI 2.192.14 25.5922.09***** 22.3921.60 29.4922.60 17.8921.19
FEV1 ml (mean9SD) 3.090.57 3.190.63 3.190.63 3.190.65 3.190.61
FVC ml (mean9SD) 3.690.63 3.790.78 3.790.78 3.890.79 3.790.73
FEV1/FVC (mean9SD) 83.695.69 83.2595.95 83.695.40 82.896.69 83.495.82
OSAHS, obstructive sleep apnea-hypopnea syndrome; ESS, Epworth sleepiness scale; BMI, body mass index; BP, blood pressure; AHI,
apnea-hypopnea index; SD, standard deviation; ODI, oxygen desaturation index; FEV1, first second forced expiratory volume; FVC,
forced vital capacity.
*Patients with OSAHS were more somnolent than control subjects (p0.013). **Hypertensive OSAHS patients had a higher ESS score
than normotensive OSAHS patients (p0.015). ***BMI was significantly higher in hypertensive OSAHS patients than in normotensive
OSAHS patients (p0.032). ****Average blood pressure was significantly higher in hypertensive OSAHS patients than in normotensive
patients (p0.01) and in controls (p0.014). *****Desaturation index was significantly altered in OSAHS patients in comparison with
controls (p0.0001).






Sex (male/female) 27/26 5/6 0.07
Age (years) 42.7910.16 53910.58 0.003
Smoking status (%) 93.7 6.3 0.18
ESS 9.394.05 10.493.58 0.408







AHI 16.7917.10 33.6918.42 0.005
Mean SpO2 (%) 94.792.85 90.893.26 B0.0001
Minimal SpO2 (%) 85.698.89 75.3911.43 0.002
ODI (/h) 13.9918.64 36.6923.43 0.001
TST90 (%) 6.1912.95 20.2912.53 0.002
BNP, brain natriuretic peptide; n, number; %, percentage; ESS,
Epworth sleepiness scale; BMI, body mass index; AHI, apnea-
hypopnea index; SpO2, transcutaneous oxygen saturation; TST90,
total sleep time with SpO2 B90%; ODI, oxygen desaturation index.
Bold values indicate statistically significant difference.
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Compared with baseline, treatment with CPAP signifi-
cantly decreased BNP levels in hypertensive OSAHS
patients (from 36916.1 to 29.7914.29, pB0.001) and
in normotensive OSAHS patients (from 20910.09 to
1698.98 pg/ml, pB0.001). In contrast, BNP levels slightly
increased in controls (from 9.296.75 to 9.597.02 pg/ml,
p0.029), but there was no statistically significant differ-
ence from the baseline value (Fig. 3).
The changes in BNP levels (DBNP) were more marked in
OSAHS with higher baseline BNP levels. As the hyper-
tensive OSAHS patients had the highest baseline BNP, they
had the magnitude of the CPAP effect (p0.015, r0.72)
in comparison with normotensive OSAHS patients
(p0.03, r0.62) (Fig. 4). Moreover, we found a signifi-
cant association between the change in BNP levels and
baseline TST90 (p0.001, r0.65) (Fig. 5). In contrast,
we did not find any association with ESS, AHI, or ODI.
Discussion
Is OSAHS associated with elevated serum levels of
BNP?
In this study, we showed that the serum BNP level was
significantly increased in patients with OSAHS in compar-
ison with controls. The two groups were closely matched
for almost all confounding variables such as age, BMI,
blood pressure, and renal function. The higher blood sugar
level in the OSAHS group was the only difference. After
adjustment, a significant correlation between BNP level
and OSAHS was identified. We also show that the elevated
level of BNP is positively correlated with the severity of
OSAHS, independent of obesity. Our results indicate that
BNP is sensitive enough to detect myocardial stress caused
by OSAHS and could be used as a sensitive marker for
underlying preclinical cardiovascular changes in patients
with OSAHS (6).
Our finding is in accordance with some previous studies.
Kita et al. (14) reported increased levels of BNP during
sleep in patients with OSAHS. However, cardiovascular
diseases were not considered and the study group was
small (12 males and 2 females). Similarly, in a community-
based sample of 349 women, Ljunggren et al. (8) found a
relationship between the severity of sleep apnea during
the night and the levels of plasma BNP in the morning
that cannot be explained by known confounding factors.
The same conclusion was reached by Kaditis et al. (15)
Table 3. OSAHS classification according to baseline BNP levels (pg/ml)
Mild OSAHS Moderate OSAHS Severe OSAHS Total
BNP (pg/ml) 12.299.13* 24.4917.13 26.3912.93 22.3914.79
BNP B37 pg/ml (n,%) 10 (100) 10 (62.5) 12 (61.6) 32
BNP ]37 pg/ml (n,%) 0 (0) 6 (62.5) 5 (38.4) 11
OSAHS, obstructive sleep apnea-hypopnea syndrome; BNP, brain natriuretic peptide; n, number;%, percentage.
*The mean serum BNP level in the mild OSAHS group was significantly lower than in the severe OSAHS group (p0.029).
Fig. 1. Distribution of BNP by OSAHS severity. OSAHS,
obstructive sleep apnea-hypopnea syndrome; BNP, brain
natriuretic peptide.







BNP (pg/ml) 9.296.75 22.3914.79 B0.001
Males/females (n) 10/11 22/21 0.79
Age (years) 41.3910.07 46911.05 0.11
Smoking (%) 35.4 64.6 0.44
Average BP (mmHg) 9.490.60 9.690.70 0.33
ESS (points) 7.794.78 10.393.24 0.013
BMI (kg/m2) 32.995.90 34.296.51 0.46
AHI (events/h) 2.691.26 28916.95 B0.001
Mean SpO2 (%) 96.691.39 92.893.21 B0.001
Min SpO2 (%) 92.394.30 79.799.46 B0.001
FVC (%) 3.690.63 3.790.77 0.41







AHI, apnea-hypopnea index; BNP, brain natriuretic peptide; n,
number; %, percentage; BP, blood pressure; ESS, Epworth
sleepiness scale; BMI, body mass index; SpO2, transcutaneous
oxygen saturation; FVC, forced vital capacity; FEV1, first second
forced expiratory volume. Bold values indicate statistically
significant difference.
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in a study on children with OSAHS investigated with
overnight PSG and compared with simple snorers.
Many hypotheses have been suggested to explain how
OSAHS might contribute as a stimulus of BNP release.
It is well known that BNP is primarily secreted by the left
ventricular myocytes in response to cardiac wall stretching.
Hypoxia has also been reported to induce BNP secretion
(16). In contrast, we know that exaggerated negative
intrathoracic pressure and its repetitive fluctuations during
nightly apnea episodes markedly increases ventricular trans-
mural pressure and left ventricular afterload, as well as the
end-systolic and end-diastolic volume during sleep. Indeed,
all of them together may give rise to both pressure load and
volume expansion (17). Furthermore, sustained activation of
the sympathetic nervous system and intermittent nocturnal
hypoxemia may also contribute. Repetitive rise in blood
pressure may also add by inducing myocyte damage and
increasing blood BNP levels (18). Based on these findings,
some authors, such as Maeder et al. (19), have claimed that
the high level of BNP is a convenient marker for detecting
cardiovascular damage. Nevertheless, there is still uncertainty
about whether OSAHS affects BNP, as several other studies
have reported different data. In a prospective study on 60
consecutive patients, Hübner et al. (6) did not find any
correlation between N-terminal pro-brain natriuretic peptide
(NT-pro-BNP) and AHI or other sleep-related indices. In
multiple regression analysis, NT-pro-BNP was significantly
correlated with left ventricular ejection fraction, creatinine
clearance, and the presence of arterial hypertension but not
with AHI. Likewise, Cifçi et al. (20) evaluated 33 patients
with OSAHS and did not find statistically significant
increases in the levels of serum BNP. Consequently, they
concluded that OSAHS does not induce enough myocardial
damage to increase serum BNP levels. Tasci et al. (9) found
that OSAHS did not affect BNP levels even in hypertensive
OSAHS patients, in contrast to our study. Recently, Maeder
et al. (7) showed that significant OSAHS is associated with a
more pronounced overnight reduction in BNP. However,
they could not find any significant differences in NT-
pro-BNP between patients with moderate or severe OSAHS
and those with mild or no OSAHS.
Is BNP decreased by nasal CPAP in OSAHS?
The most important finding of our study is that CPAP
application decreased BNP levels significantly in OSAHS
patients, suggesting that CPAP therapy improves cardio-
vascular function (6). To our knowledge, this is the second
time that CPAP application has been shown to produce
a long-term reduction of BNP levels in healthy OSAHS
patients. Kita et al. (14) were the first to demonstrate that
CPAP gradually decreases the nocturnal BNP profile
from evening to morning in severe OSAHS patients. None
of the patients in that study had clinical signs of heart
or renal failure or lung disease, and they did not have any
apparent edema. More recently, Tasci et al. (9) observed
that the NT-pro-BNP in OSAHS patients is significantly
decreased after the first night of CPAP application. Here
too, the study did not include patients with congestive
heart failure, confirmed either clinically or echocardio-
graphically. Zhao et al. (21) reached the same conclusion.
However, this study was conducted in OSAHS patients
with congestive heart failure.
The mechanism of the effect of CPAP on NT-pro-BNP
levels is not clear. However, Tasci et al. (9) suggested that
Fig. 2. The BNP levels in hypertensive OSAHS were
significantly higher than in normotensive OSAHS patients
(18.05911.73 pg/ml) (p0.039) and controls (9.2696.75
pg/ml) (p0.001). Normotensive OSAHS patients had
higher baseline BNP levels in comparison with controls,
but there was no statistically significant difference between
the two groups (p0.058). Boxes represent values within the
interquartile ranges. Whiskers represent the data range, and
the lines across the boxes represent the median values. The
bottom and top of the boxes are the 25th and 75th
percentiles, respectively. OSAHS, obstructive sleep apnea-
hypopnea syndrome; BNP, brain natriuretic peptide.
Fig. 3. Effect of CPAP treatment in hypertensive (n11)
and normotensive (n12) OSAHS patients compared with
controls (n21). OSAHS, obstructive sleep apnea-hypopnea
syndrome; BNP, brain natriuretic peptide; CPAP, continuous
positive airway pressure. Red: baseline levels; blue: levels
after 6 months of CPAP therapy.
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the main mechanism might be the Mueller maneuver
because the application of CPAP normalizes intrathor-
acic pressure, which decreases by up to 50 mmHg during
apneas (22). This barometric change leads to a normal-
ization of increased systolic transmural pressures and
left ventricular afterload. Curiously, we found that the
magnitude of the effect was greater in patients with
higher baseline BNP levels, hypertensive patients, and
those with the most nocturnal prolonged desaturation.
These results suggest that increased cardiovascular risk
factors are associated with a more marked effect of CPAP.
In contrast to our data, most studies did not find any
effect of CPAP on BNP levels, neither short term nor
long term. Maeder et al. (7) showed that short-term CPAP
used on 21 patients with moderate/severe OSAHS did not
affect plasma concentrations of NT-pro-BNP before or
after sleep, and changes during sleep did not significantly
differ between the nights with and without CPAP. On the
other hand, Hübner et al. (6) observed an interesting long-
term lowering effect on NT-pro-BNP levels by CPAP
therapy in six patients with pathologically elevated levels
before treatment. However, this observation was not
statistically significant, probably due to the small subset
group. Similarly, Colish et al. (23) prospectively followed
47 patients with severe OSAHS under prolonged CPAP
therapy. At baseline, the NT-pro-BNP levels were within
normal limits for the entire population. At 3, 6, and 12
months of follow-up, there was no significant change in
NT-pro-BNP levels compared with baseline. In agreement
with these data, Cifçi et al. (20) did not detect any
significant difference in the levels of pro-BNP after
6 months of CPAP therapy. Only patients with moderate
or severe OSAHS were included and none had congestive
heart failure.
In view of all of these conflicting data, it is difficult to
draw any clear conclusions about the acute and long-term
effects of CPAP on BNP levels in OSHAS patients. Any
result needs careful interpretation due to the possible
role of other confounding variables (6).
Limitations and strengths of this study
The strengths of this study include comparison of the
OSAHS group to a control group with adjustment for
relevant confounding covariates. Moreover, a group of
patients with untreated OSAHS was compared with
patients treated by CPAP. Additionally, all the blood
samples were collected the morning after the nocturnal
recording. The limitations of our study were the small size
of the study group and the use of polygraph type 3 instead
of standardized polysomnographic recording. Moreover,
because we only evaluated patients with OSAHS without
preexisting cardiac diseases, future studies are required
to evaluate the effects of compliant CPAP therapy on












Fig. 4. In linear regression, the changes in BNP levels in 23
patients OSAHS after 6-month CPAP treatment were more
important in OSAHS patients with higher baseline BNP levels.
Note that hypertensive OSAHS patients had the higher delta
BNP (T6T0) (p0.015, r0.72) in comparison with normo-
tensive OSAHS patients (p0.03, r0.62). OSAHS, obstruc-
tive sleep apnea-hypopnea syndrome; BNP, brain natriuretic
peptide; CPAP, positive airways pressure. Blue: hypertensive
OSAHS; red: normotensive OSAHS.











Fig. 5. In linear regression, the changes in BNP levels in
23 patients OSAHS after 6-month CPAP treatment were more
pronounced in OSAHS patients with prolonged nocturnal
desaturation (TST90) (r0.65, p0.001). OSAHS,
obstructive sleep apnea-hypopnea syndrome. BNP, brain
natriuretic peptide; CPAP, continuous positive airway pressure.
Serum BNP level change under nasal CPAP
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Conclusion
According to our results, BNP seems to be sensitive
enough to detect myocardial stress caused by OSAHS.
It might then be suggested as a potential marker for
screening of preclinical cardiovascular damage in patients
with untreated OSAHS. However, it should be noted that
these findings are purely of an associative nature and do
not imply cause and effect. Therefore, more research is
needed before making any definitive conclusions.
The most important finding of our study is the
decrease in daytime BNP levels after long-term CPAP
application. This effect was more pronounced with higher
baseline BNP levels. This finding provides further sup-
port for understanding how CPAP therapy can improve
cardiovascular outcomes, as demonstrated by Marin
et al. (24). We also suggest that the BNP level can be
useful for predicting the cardiac effects of CPAP therapy
in the earlier stages of OSAHS without heart failure.
Here again, because of the conflicting data in the
literature, further studies on larger samples and rigorous
methods are needed to identify potential applications that
might be derived from the findings of the present study.
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